mk-0616
merck
[]
efficacy and safety of the oral pcsk9 inhibitor mk-0616 in phase 2b rct. #acc2023 
MD,PhD. Postdoc Fellow-Cardiologist. University of Naples Federico II @uninaIT & CPC Clinical Research @cpcresearch, University of Colorado @CUAnschutz 🇮🇹🇺🇸